eXmoor and Kincell team to meet CGT demand

exMoor and Kincell aim to advance development and manufacturing services in Europe and the US to meet growing CGT demands for global clients.

Millie Nelson, Editor

September 5, 2023

2 Min Read
eXmoor and Kincell team to meet CGT demand
DepositPhotos/AntonMatyukha

eXmoor and Kincell aim to advance development and manufacturing services in Europe and the US to meet growing CGT demands for global clients.

The two contract development manufacturing organizations (CDMOs) have partnered to bring together both companies’ CGT manufacturing capabilities across Europe and the US. The collaboration, of which financials have not been disclosed, looks to enable customers to access a global development and production footprint with different offerings from both parties.

The partnership, of which financial details have not been disclosed, aims to bring together both companies’ CGT manufacturing capabilities across Europe and the US. In turn, this enables customers to access a global development and production footprint with different offerings from both parties.

Depositphotos_246481784_S-300x200.jpg

DepositPhotos/AntonMatyukha

“The partnership is needed to better support our customers. UK companies who carry out manufacturing with  eXmoor for Phase I/II trials in the UK inevitably include the US in their Phase III and commercial ambitions – we can now deliver this via Kincell without them needing to source another CMDO using a resource intensive search and selection exercise. Likewise, US companies who carry out manufacturing with Kincell for Phase I/II trials may well want to include the UK/EU in their Phase III and commercial ambitions, and eXmoor can deliver this for them,” Angela Osborne, CEO of eXmoor  told BioProcess Insider.

“Kincell is currently focused on delivering autologous and allogeneic cell therapies, where a lentiviral vector is often required for these therapies, and eXmoor will provide this. eXmoor will also provide the iPSC derived products or AAV products where required by Kincell’s customers.”

The partnership will work through a Joint Steering Committee, which will be implemented through face-face meetings involving the technical and leadership personnel. Osbourne said as each party get to know their respective sites and working style, “we will prioritize developing seamless ways of working between us, resulting in joint attendance and exhibiting at conferences, and the consideration of joint contracting to present a single face to the customer.”

There is no time-limit to this partnership with eXmoor and Kincell viewing the collaboration as a “long-term relationship.”

eXmoor established its CDMO status in May with $35 million funding.

About the Author(s)

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like